国产亚洲精品日韩av在,久久综合九色综合久99,亚洲一区二区视频在线观看

去乙基阿莫地喹

NMR下載 COA and HPLC MSDS下載
names：
N-Desethyl amodiaquine
CAS號(hào)：
79352-78-6
MDL Number： MFCD08063555
MF(分子式)： C18H18ClN3O MW(分子量)： 327.81
EINECS: Reaxys Number:
Pubchem ID:122068 Brand:BIOFOUNT

去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)屬于一種有機(jī)化合物，稱為4-氨基喹啉。這些是含有與喹啉環(huán)系統(tǒng)的4-位連接的氨基的有機(jī)化合物。去乙基阿莫地喹被認(rèn)為是實(shí)際上不溶的（在水中）并且是相對(duì)中性的分子。在人的肝臟和腎臟組織中發(fā)現(xiàn)了去乙基阿莫地喹，在尿液和血液等多種生物流體中也發(fā)現(xiàn)了去乙基阿莫地喹。在細(xì)胞內(nèi)，去乙基阿莫地喹主要位于細(xì)胞質(zhì)和膜中。

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫存描述	數(shù)量	總計(jì) (￥)
YZM000809-10mg	10mg	99.9%	￥ 5568.00	￥ 5568.00		3-5天	- +	￥ 0.00
YZM000809-5mg	5mg	99.9%	￥ 2980.00	￥ 2980.00		3-5天	- +	￥ 0.00

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購物車立即購買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine);N-脫乙基阿莫地喹
英文別名	N-Desethyl amodiaquine(79352-78-6);desethylamodiaquine;Monodesethylamodiaquine
CAS號(hào)	79352-78-6
Inchi	InChI=1S/C18H18ClN3O/c1-2-20-11-12-9-14(4-6-18(12)23)22-16-7-8-21-17-10-13(19)3-5-15(16)17/h3-10,20,23H,2,11H2,1H3,(H,21,22)
InchiKey	VRXFDHAGFYWGHT-UHFFFAOYSA-N
分子式 Formula	C18H18ClN3O
分子量 Molecular Weight	327.81
溶解度Solubility	生物體外In Vitro:DMSO溶解度125 mg/mL(381.32 mM;Need ultrasonic)
性狀	淺黃色至黃色固體粉末
儲(chǔ)藏條件 Storage conditions	storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)

去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)實(shí)驗(yàn)注意事項(xiàng)：
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡，穿戴防護(hù)服和口罩，佩戴手套，避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ)，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

N-Desethyl amodiaquine(79352-78-6) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine),去乙基阿莫地喹試劑,去乙基阿莫地喹抑制劑,去乙基阿莫地喹的作用,去乙基阿莫地喹的生產(chǎn),去乙基阿莫地喹的廠家,去乙基阿莫地喹的價(jià)格,去乙基阿莫地喹的合成,去乙基阿莫地喹的純度,去乙基阿莫地喹的外觀,去乙基阿莫地喹的MSDS

產(chǎn)品說明	去乙基阿莫地喹(79352-78-6,N-Desethyl amodiaquine)是 Amodiaquine 的主要生物活性代謝產(chǎn)物,去乙基阿莫地喹是一種抗寄生蟲劑
Introduction	N-Desethyl amodiaquine(79352-78-6,去乙基阿莫地喹) is the main bioactive metabolite of Amodiaquine, and desethyl amodiaquine is an antiparasitic agent
Application1
Application2
Application3

警示圖
危險(xiǎn)性	warning
危險(xiǎn)性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害
安全防護(hù)	P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理
備注	實(shí)驗(yàn)過程中防止吸入、食入，做好安全防護(hù)

象形圖
信號(hào)警告	Warning
GHS危險(xiǎn)說明	Aggregated GHS information provided by 40 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
防范說明代碼	P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells PMID 31629065;

Influence of MAMA decoction, an Herbal Antimalarial, on the Pharmacokinetics of Amodiaquine in Mice PMID 31642009; European journal of drug metabolism and pharmacokinetics 2020 Feb; 45(1):81-88

Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children PMID 31652336

Influence of LAR and VAR on Para-Aminopyridine Antimalarials Targetting Haematin in Chloroquine-Resistance PMID 27483471; PloS one 2016; 11(8):e0160091

Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015 PMID 28302108; Malaria journal 2017 03; 16(1):118

In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of continued use of 4-aminoquinolines in East Africa
Abstract:In light of reports of increasing resistance of parasites to amodiaquine in African countries in which Plasmodium falciparum is endemic as well as the paucity of recent in vitro sensitivity data, we assessed the in vivo and in vitro sensitivity to amodiaquine of P. falciparum isolates from 128 pediatric outpatients (0.5-10 years old) in Pingilikani, Kilifi District, Kenya, who were treated with amodiaquine (10 mg/kg/day for 3 days). The polymerase chain reaction-corrected parasitological cure rate on day 28 (by Kaplan-Meier analysis) was 82% (95% confidence interval [CI], 74%-88%). Twenty-six percent (17/66) of tested pretreatment P. falciparum field isolates had 50% in vitro growth inhibition at concentrations of N-desethyl-amodiaquine (DEAQ)-the major biologically active metabolite of amodiaquine-above the proposed resistance threshold of 60 nmol/L, but baseline median DEAQ 50% inhibitory concentration values were not associated with subsequent risk of asexual parasite recrudescence (29 nmol/L [95% CI, 23-170 nmol/L] and 34 nmol/L [95% CI, 30-46 nmol/L] for patients with and those without recrudescences, respectively). The median absolute neutrophil count dropped by 1.3 X 10(3) cells/microL (95% CI, -1.7 X 10(3) to -0.7 X 10(3) cells/microL) between days 0 and 28. The high prevalence of in vitro and in vivo resistance precludes the use of amodiaquine on its own as second-line treatment. These findings also suggest that the value of amodiaquine combinations as first- or second-line treatment in areas with similar patterns of 4-aminoquinoline resistance should be reassessed.

對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開